Anadrol

Oxymetholone is a DHT-derived anabolic steroid developed by Syntex Pharmaceuticals in 1960 for the treatment of anemia and osteoporosis. It carries a 2-hydroxymethylene modification that dramatically increases its anabolic potency, making it one of the most powerful oral steroids ever produced. Despite its DHT lineage, Oxymetholone exhibits estrogenic activity through a mechanism that does not involve aromatase — it directly activates estrogen receptors, which is why aromatase inhibitors alone may not fully manage its estrogenic side effects.

The compound's mechanism of action involves profound stimulation of erythropoiesis (red blood cell production), dramatic increases in nitrogen retention, and robust activation of the androgen receptor in skeletal muscle tissue. Oxymetholone also increases levels of insulin-like growth factor 1 (IGF-1) and promotes substantial intracellular water retention within muscle cells, contributing to the rapid and visible fullness researchers observe. Weight gains of 10–15 pounds within the first two weeks of a research protocol are commonly reported in the literature.

Anadrol is the compound of choice when maximum mass and strength accrual in the shortest timeframe is the primary objective. It is unmatched among orals for its ability to push bodyweight and strength ceilings rapidly. The cosmetic result is a full, rounded muscularity — distinct from the dry, hard aesthetic produced by Winstrol or Anavar. Researchers should note that a significant portion of the weight gained includes intracellular water, which recedes upon discontinuation.

This is an advanced-tier compound. It is not recommended for first-time researchers due to its potency and the management it demands. Experienced researchers typically deploy Anadrol as a kickstart to a longer injectable cycle (most commonly the first 4–6 weeks alongside Testosterone and Deca Durabolin or Equipoise). It pairs well with aromatase inhibitors and liver-support agents.

Oxymetholone has a half-life of approximately 8–9 hours, supporting once- or twice-daily dosing. Research dosages typically range from 25–100 mg daily, with 50 mg being the most common starting point. This is a 17-alpha-alkylated compound with meaningful hepatotoxicity — liver enzymes (ALT, AST) will elevate during use. Administration should not exceed 4–6 weeks without bloodwork, and TUDCA (250–500 mg daily) is strongly recommended throughout. Blood pressure monitoring is essential, as Oxymetholone can cause significant fluid-mediated elevations.